Corisma
Bethany
About Corisma
Spun out of the Bonde Artificial Heart Lab at Yale University, Bonde Innovations is developing an innovative, catheter implanted circulatory assist device, CoRISMA, to treat Class 3 and Class 4 heart failure patients. With $2M+ grant funding, CoRISMA has been designed to improve patients' quality of life and reduce cost and invasiveness associated with the current therapies. All the components of the devices have been prototyped and tested at Yale.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $27.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2021)
- Website: corismacv.com
- Phone: [email protected]
Industries & Categories
Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/corisma-31654 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.